JB Global approves sale of JAT's Neurio range
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Jat Energy (ASX:JAT) has informed the market today that JD Global, China’s largest retailer by revenue, has approved the sale of Sunnya’s Neurio branded products.
The Neurio range will be sold to Chinese consumers on JD Global’s cross border and supermarket platforms: www.JD.com and www.JD.hk.
JD has placed orders on the following products:
- Neurio – Lactoferrin milk powder, and
- Neurio – DHA Algae oil softgel
JD services more than 266 million annual active users, and claims to possess the largest fulfilment infrastructure of any e-commerce company in China. Covering 2,380 counties and districts, JD has seven fulfilment centres and more than 400 warehouses.
Lactoferrin is a natural antibacterial agent, found in mammalian milk, tears and saliva.
Overall this is an early stage play and as such any investment decision should be made with caution and professional financial advice should be sought.
JAT Executive Director Wilton Yao spoke on the development, “We continue to receive positive responses to Neurio products, from everyone we talk to. I have high expectations for this brand. Buyers are impressed with its immune system boost.”
As previously announced, JAT has agreed to purchase 51% of Sunnya Pty Limited, subject to shareholder approval. The Neurio range are products supplied by Sunnya Pty Limited.
Sunnya has agreed to supply JAT the entirety of the Neurio product required to fulfil the JD agreement over the next 12 months, regardless of whether the Sunnya acquisition proceeds.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.